More Stress Expected as Lockdowns Continue, People Get Sick, Unemployment Persists
Rare research on the effects of a pandemic undertaken during an ongoing disaster shows that COVID-19 has severely affected people’s daily emotional lives and mental health, increasing their stresses the longer lockdowns, fear of getting sick and financial strains continue.
Patients at UC Davis Health on Thursday (Aug. 20) became the first in Sacramento to receive a vaccine candidate for COVID-19, which is part of a major clinical trial involving 30,000 participants worldwide.
The six people who received the injections are part of a late-stage study that will enroll about 200 participants through UC Davis Health’s clinical trials program.
Humans are not the only species facing a potential threat from SARS-CoV-2, the novel coronavirus that causes COVID-19, according to a new study from the University of California, Davis.
An international team of scientists used genomic analysis to compare the main cellular receptor for the virus in humans — angiotensin converting enzyme-2, or ACE2 — in 410 different species of vertebrates, including birds, fish, amphibians, reptiles and mammals.
The Cypress Building was a blur of activity this week as a clinical trials team prepped and launched its first COVID-19 vaccine study. It’s just one of 14 clinical trials for the disease taking place at UC Davis Health. There are also a number of related activities, all focusing on addressing the challenges of the novel coronavirus.
Influenza viruses can spread through the air on dust, fibers and other microscopic particles, according to new research from the University of California, Davis, and the Icahn School of Medicine at Mount Sinai. The findings, with obvious implications for coronavirus transmission as well as influenza, are published Aug. 18 in Nature Communications.
The COVID-19 pandemic is a health challenge of global proportions. UC Davis research teams are racing to find treatments for the deadly disease. The university, with its unique range of both human and veterinary medicine capabilities, now has 38 novel coronavirus studies underway at its campuses in Davis and Sacramento. This critically important work includes efforts to help develop a vaccine that would prevent infection by the SARS-CoV-2 virus and reduce its devastating effects.
Sacramento’s academic medical center is one of only 120 sites chosen for global study that could lead to much-needed vaccine by year’s end
(SACRAMENTO) —
UC Davis Health today announced a partnership with Pfizer Inc. and BioNTech SE to participate in a global study of an investigational vaccine against COVID-19, adding a significant component to the university’s response to the deadly coronavirus pandemic.
